Tetra Pharm Technologies and Kvantify will Develop Drugs for the Endocannabinoid System

Biopharmaceutical and quantum computing, an alliance with potential. Tetra Pharm Technologies, a Danish biopharmaceutical company created in 2018, and Kvantify, a company that offers quantum software services also established in Copenhagen, have announced their intention to partner to “revolutionize drug discovery.”

This partnership could transform the landscape of drug discovery targeting the endocannabinoid system (ECS), which could lead, according to the statement signed by the two companies, to significant advances in therapeutic options for patients.

Tetra Pharm Technologies CEO Martin Rose said: “ This partnership will accelerate our drug development process and significantly expand our pipeline of drug candidates in 2024.”

The duo intends to delve deeper into the complexities of endocannabinoid receptors and their interactions with potential drugs. According to the aforementioned statement, Tetra Pharm Technologies currently has eleven drug candidates in the development phase, “each targeting specific receptors with different modes of action,” and more candidates on the way.

Partnership betweeen Tetra Pharm Technologies and Kvantify could transform the landscape of drug discovery targeting the endocannabinoid system

The pharmaceutical company’s scientific director, Morten Allesø, indicated that, with Kvantify, Tetra Pharm Technologies will be able to “perform much broader screening and more effectively identify the key structural attributes of our drug candidates to guide our in vitro cellular pharmacology.”

The statement explains that the collaboration between the companies includes a screening of almost a thousand molecular combinations suspected of acting as ligands for endocannabinoid receptors , which “is carried out using Kvantify’s CNS module, which provides Tetra Pharm Technologies with additional information about the propensity for penetration of the blood-brain barrier.”

Kvantify’s director of strategic alliances, Nils Anton Berglund, highlights that “ The ECS has been underutilized in drug discovery and represents a huge opportunity for innovation.” The company’s CEO, Hans Henrik Knudsen, added: “The combination of Tetra Pharm Technologies’ novel drug delivery technology with Kvantify’s computational drug discovery platform constitutes a very exciting synergy that will facilitate faster development and effective of new drugs.

Tetra Pharm Technologies is a Danish biopharmaceutical company created in 2018 with the mission of researching and developing drugs for the treatment of ECS-related diseases.

__

(Featured image by TheDigitalArtist via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us